Activin receptor
From Proteopedia
(Difference between revisions)
| Line 29: | Line 29: | ||
**[[6acr]], [[6gi6]], [[6gip]], [[6gin]], [[4bgg]], [[3q4u]], [[3mtf]], [[6t6d]], [[6jux]], [[6tnb]], [[6tn8]], [[6t8n]], [[6szm]], [[6eix]], [[6srh]], [[5oy6]], [[6z36]], [[6zgc]], [[7a21]], [[7c3g]] - hAcvr1 kinase domain (mutant) + inhibitor<br /> | **[[6acr]], [[6gi6]], [[6gip]], [[6gin]], [[4bgg]], [[3q4u]], [[3mtf]], [[6t6d]], [[6jux]], [[6tnb]], [[6tn8]], [[6t8n]], [[6szm]], [[6eix]], [[6srh]], [[5oy6]], [[6z36]], [[6zgc]], [[7a21]], [[7c3g]] - hAcvr1 kinase domain (mutant) + inhibitor<br /> | ||
**[[3h9r]], [[4c02]], [[6i1s]] - hAcvr1 kinase domain + FKBP12 + inhibitor<br /> | **[[3h9r]], [[4c02]], [[6i1s]] - hAcvr1 kinase domain + FKBP12 + inhibitor<br /> | ||
| + | **[[7nns]] - hAcvr1 kinase domain + drug<br /> | ||
*Activin receptor type 2 | *Activin receptor type 2 | ||
| Line 38: | Line 39: | ||
**[[4asx]], [[3soc]], [[3q4t]] - hAcvr2A kinase domain + inhibitor<br /> | **[[4asx]], [[3soc]], [[3q4t]] - hAcvr2A kinase domain + inhibitor<br /> | ||
**[[5nh3]] - hAcvr2A LBD + antibody<br /> | **[[5nh3]] - hAcvr2A LBD + antibody<br /> | ||
| + | **[[7u5p]] - hAcvr2A LBD + inhibin<br /> | ||
**[[2goo]], [[2h64]], [[2h62]] - mAcvr2A LBD + BMP-2 + ALK3<br /> | **[[2goo]], [[2h64]], [[2h62]] - mAcvr2A LBD + BMP-2 + ALK3<br /> | ||
**[[1lx5]] - mAcvr2A LBD + BMP-7<br /> | **[[1lx5]] - mAcvr2A LBD + BMP-7<br /> | ||
| Line 45: | Line 47: | ||
**[[2qlu]] - hAcvr2B kinase domain<br /> | **[[2qlu]] - hAcvr2B kinase domain<br /> | ||
**[[5ngv]], [[5nhr]] - hAcvr2B LBD + antibody<br /> | **[[5ngv]], [[5nhr]] - hAcvr2B LBD + antibody<br /> | ||
| + | **[[7oly]] - hAcvr2B LBD + hAcvr1B LBD + antibody + inhibin<br /> | ||
| + | **[[7mrz]] - hAcvr2B LBD + hAcvr1B LBD + antibody + GDF11<br /> | ||
**[[1s4y]] - mAcvr2B LBD + inhibin<br /> | **[[1s4y]] - mAcvr2B LBD + inhibin<br /> | ||
**[[1nyu]] - rAcvr2B LBD + inhibin - rat<br /> | **[[1nyu]] - rAcvr2B LBD + inhibin - rat<br /> | ||
Revision as of 08:02, 22 August 2022
| |||||||||||
3D structures of activin receptor
Updated on 22-August-2022
References
- ↑ Han HQ, Zhou X, Mitch WE, Goldberg AL. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol. 2013 Oct;45(10):2333-47. doi:, 10.1016/j.biocel.2013.05.019. Epub 2013 May 28. PMID:23721881 doi:http://dx.doi.org/10.1016/j.biocel.2013.05.019
- ↑ Williams E, Bullock AN. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2. Bone. 2017 Sep 12. pii: S8756-3282(17)30340-X. doi: 10.1016/j.bone.2017.09.004. PMID:28918311 doi:http://dx.doi.org/10.1016/j.bone.2017.09.004
- ↑ Roh JD, Hobson R, Chaudhari V, Quintero P, Yeri A, Benson M, Xiao C, Zlotoff D, Bezzerides V, Houstis N, Platt C, Damilano F, Lindman BR, Elmariah S, Biersmith M, Lee SJ, Seidman CE, Seidman JG, Gerszten RE, Lach-Trifilieff E, Glass DJ, Rosenzweig A. Activin type II receptor signaling in cardiac aging and heart failure. Sci Transl Med. 2019 Mar 6;11(482). pii: 11/482/eaau8680. doi:, 10.1126/scitranslmed.aau8680. PMID:30842316 doi:http://dx.doi.org/10.1126/scitranslmed.aau8680
- ↑ Mohedas AH, Wang Y, Sanvitale CE, Canning P, Choi S, Xing X, Bullock AN, Cuny GD, Yu PB. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 2014 Oct 9;57(19):7900-15. doi: 10.1021/jm501177w. Epub 2014 Sep 4. PMID:25101911 doi:http://dx.doi.org/10.1021/jm501177w
